Last reviewed · How we verify

NCT07374952

Minimal Effective Volume 90% for Double-injection Costoclavicular Block

Not yet recruiting Phase 4 Last updated 20 February 2026
What this trial tests

Phase 4 trial testing Ultrasound-guided double-injection costoclavicular nerve block with same previous volume in Brachial Plexus Blocks in 60 participants. Not yet recruiting.

Timeline
1 February 2026
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre
PhasePhase 4
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingquadruple
Primary purposesupportive care
Enrollment60
Start date1 February 2026
Primary completion31 December 2026
Estimated completion31 December 2026

Drugs / interventions tested

Conditions studied

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Who can join

Adults 18 to 70, any sex, with Brachial Plexus Blocks or Lidocaine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In 2020, a trial demonstrated that a 2-injection technique constitutes the optimal method for the costoclavicular block. This study aims to determine the minimum amount of medication required to achieve a successful double-injection costoclavicular nerve. Block dose assignment will be done using an up-and-down sequential method, called the Biased Coin Design (BCD). The double-injection technique for US-guided costoclavicular block consists in depositing two thirds of the LA volume in the deep compartment (to anesthetize the posterior and medial cords), and one third of the injectate in the superficial compartment (to anesthetize the lateral cord). The ED90 will be calculated using isotonic regression with a 95% confidence interval derived by bootstrapping.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other McGill University Health Centre/Research Institute of the McGill University Health Centre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07374952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing